Gregg Blevins

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Bibiana Bielekova, Nancy Richert, Gregg Blevins et al. · Proceedings of the National Academy of Sciences · 2004 · 313 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke

David F. Moore, Hong Li, Neal Jeffries et al. · Circulation · 2005 · 227 citations · Full text

Life Sciences, Molecular Biology, Neurology +13

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

Luanne M. Metz, David K.B. Li, Anthony Traboulsee et al. · New England Journal of Medicine · 2017 · 187 citations · Full text

Medicine, Neurology, Pharmacotherapy +14